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Abstract 
This paper presents a novel strategy for the prevention of ventilator-associated 
pneumonia that involves coating poly(vinylchloride, PVC) Endotracheal Tubes (ET) with 
hydrogels that may be subsequently used to entrap nebulised antimicrobial solutions.  
Candidate hydrogels were prepared containing a range of ratios of 
hydroxyethylmethacrylate (HEMA) and methacrylic acid (MAA) from 100:0 to 70:30 
using free radical polymerisation and, when required, simultaneous attachment to PVC 
was performed.  The mechanical properties, glass transition temperatures, swelling 
kinetics, uptake of gentamicin from an aqueous medium and gentamicin release were 
characterised.  Increasing the MAA content of the hydrogels significantly decreased the 
ultimate tensile strength, % elongation at break, Young’s modulus and increased the 
glass transition temperature, the swelling ratio and gentamicin uptake.  Microbial 
(Staphylococcus aureus and Pseudomonas aeruginosa) adherence to control (drug-free) 
hydrogels was observed however; whilst adherence to gentamicin-containing p(HEMA) 
occurred, no adherence occurred to gentamicin-containing HEMA: MAA copolymers. 
Antimicrobial persistence of gentamicin-containing hydrogels was examined by 
determining the zone of inhibition against each microorganism on successive days.   
Hydrogel composition affected the observed antimicrobial persistence, with the 
hydrogel composed of 70: 30 HEMA: MAA exhibiting > 20 days persistence against S. 
aureus and P. aeruginosa, respectively.  To simulate clinical use, the hydrogels (coated 
onto PVC) were firstly exposed to a nebulised solution of gentamicin (4mL, 80mg for 20 
minutes), and then to nebulised bacteria (4 mL circa 1 x 109 colony forming units mL-1, 
30 mins).  Viable bacteria were not observed on the gentamicin-treated p(HEMA: MAA) 
copolymers whereas growth was observed on gentamicin-treated p(HEMA).  In light of 
the excellent antimicrobial activity and physicochemical properties, p(HEMA: MAA) 
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copolymers composed of ratios of 80: 20 or 70: 30 HEMA: MAA were identified as 
potentially useful coatings of endotracheal tubes to be used in conjunction with the 
clinical nebulisation of gentamicin and designed for the prevention of ventilator-
associated pneumonia.  
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1. Introduction 
It has been widely reported that mechanical ventilation increases the risk of nosocomial 
pneumonia by a factor of 6 to 211-5. Endotracheal intubation can facilitate the movement 
of organisms from the oropharynx into the trachea. Leakage around the cuff of the 
Endotracheal (ET) Tube allows pooled secretions above the cuff to enter the trachea 
and bronchi6. Bacteria amass on the surface of the ET tube, become irreversibly 
attached, producing extracellular polysaccharides and form a biofilm, where the sessile 
organisms are protected from host defences7-9. Assisted by ventilator flow or by 
suctioning, biofilm encased bacteria may become dislodged and travel into the lower 
airways10, resulting in ventilator associated pneumonia and the attendant associated 
considerable morbidity, mortality and increased hospital care costs11.  
 
To optimise the performance of the ET tube, methods that can reduce or eliminate 
bacterial colonisation and/or augment the efficacy of antibiotics delivered locally or 
systemically should be pursued5, 12. Technologies under consideration include 
subglottic secretion pooling (both above13 and below the cuff14), cuff design and 
operation and the use of antimicrobial-coated ET tubes5.  The role of antimicrobial 
coatings to affect the resistance of the ET tube to biofilm formation (and hence 
ventilator associated pneumonia) has been examined in a number of studies.  For 
example, Berra et al.. compared the clinical ability of silver sulfadiazine coated and non-
coated (control) ET tubes to prevent bacterial colonisation and concluded that the 
antibiotic-coating prevented bacterial colonisation of the endotracheal tube for up to 
24h intubation15.  Similarly, the ability of a silver-coated ET tube to delay the rate and 
extent of bacterial colonisation and bacterial bioburden has been reported16 whereas 
the ability of a silver sulphadiazine/chlorhexidine coating to eliminate/reduce bacterial 
 5 
colonisation in a sheep model has been described17.  Contrary to these reports, in a 
clinical study, Kaflon et al.18 reported that silver-impregnated multi-lumen catheters 
were not associated with a lower colonisation rate than their non-silver impregnated 
counterparts when evaluated in a clinical scenario whereas Desai et al.. concluded that 
impregnation of catheters with silver or nitrofurazone did not significantly affect 
bacterial adherence in comparison to control catheters19.  Whilst the evidence generally 
confirms the affirmative role of local antimicrobial delivery, it is appreciated that the 
delivery of the antimicrobial agent from such coatings is not fully understood nor 
optimised, particularly within the respiratory environment in which the volume of fluid 
for drug elution is limited.   
  
In an innovative strategy, the authors (Adair et al..) described the use of nebulised 
gentamicin for the prevention of bacterial biofilm on ET tubes and hence ventilator 
associated pneumonia10.  In a clinical study the authors reported that high 
concentrations of gentamicin were attained within the lumen of the ET tube following 
nebulisation resulting in an improved strategy for the prevention of ET tube biofilm 
when compared with parenterally administered cefoxatime.   Accordingly, this study 
proved that if sufficient concentrations of antimicrobial agent are obtained within the 
lumen of the ET tube ventilator-associated pneumonia might be prevented.  One of the 
limitations of this approach is the need for frequent nebulisation due to the negligible 
retention of the nebulised antibiotic at the luminal surface of the ET tube.   Whilst it has 
been reported that there is minimal systemic absorption of gentamicin and good 
tolerance within the airways when administered by nebulisation20, 21, it is clinically 
preferable to minimise the exposure of patients to antimicrobial agents to abate the 
development of multidrug resistant pathogens22-24.   
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To address these concerns this study describes a pharmaceutical strategy in which 
candidate hydrogels are used as luminal coatings of ET tubes to specifically entrap 
nebulised antimicrobial solutions (gentamicin in this study).  These coatings will 
therefore act as a platform for the subsequent delivery of gentamicin to bacteria 
adherent on the surface of the ET tube and hence reduce the frequency of nebulisation.   
This approach obviates the need to preload the ET tube with antimicrobial agent 
and allows the clinician to accurately control the usage of antimicrobial agent, 
thereby minimising the emergence of microbial resistance.  This is the first report of 
the use of capture coatings for nebulised antimicrobial solutions and offers an exciting 
pharmaceutical strategy to reduce/prevent nosocomial pneumonia in the intensive care 
unit. 
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2. Materials and Methods 
2.1 Materials 
2,2’-Azo-bis(2-methylpropionitrile) (AIBN) was purchased from BDH Laboratory 
Supplies (Poole, England). Mueller Hinton Agar (MHA) and Mueller Hinton Broth 
(MHB) were obtained from Oxoid Ltd (Basingstoke, England).  Gentamicin sulfate 
USP and Tris base [tris(hydroxymethyl)aminomethane] were supplied by Taresh 
Chemicals (Banbridge, UK) and Melford Laboratories Ltd (Suffolk, England), 
respectively. 2-Hydroxyethyl methacrylate (HEMA) and methacrylic acid (MAA) 
were purchased from Lancaster (Eastgate, England).  Medical grade PVC 
emulsion was obtained from Rusch Manufacturing Ltd. (Lurgan, Northern Ireland).  
PVC films were obtained from Goodfellow Cambridge Ltd. (Cambridgeshire, UK).  
All other chemicals were obtained from Sigma-Aldrich Co Ltd (Dorset England). 
 
2.2 Bacterial isolates 
The clinical isolates used in this study, namely Staphylococcus aureus and 
Pseudomonas aeruginosa, originated from microbial biofilm present on the surface of 
retrieved PVC endotracheal tubes from the intensive care unit of The Royal Victoria 
Hospital, Belfast. The organisms were maintained on beads (Protect Bacterial Preserve 
System, Technical Services Consultants Ltd., UK) and on agar in 10% glycerol at -
70°C.  Subculturing was performed at three monthly intervals, on MHA slopes stored at 
4°C. 
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2.3 Preparation of hydrogels and hydrogel-coated poly(vinyl chloride) 
A series of hydrogels were prepared by free radical polymerisation of 2-
hydroxyethylmethacrylate and methacrylic acid (10, 20, 30 % w/w) using 1.0% w/w 
2,2’-Azo-bis(2-methylpropionitrile) (AIBN) as an initiator, and cross-linked using 0.5% 
w/w ethylene glycol dimethacrylate, as previously described by the authors25, 26.   The 
monomer systems (including cross-linker and initiator) were injected into a mould 
compromising two glass sheets (150 x 100mm), which contained a loop of silicone 
tubing between a sheet of silicone coated release liner, and clamped together with 
bulldog clips to avoid leakage. The mould was then placed in a vacuum oven at 60°C 
for 18 hours, following which, the polymer was removed and washed in deionised water 
for 14 days to remove any unreacted monomers. All hydrogels were then stored in 
deionised water until required for analysis. 
 
Poly(vinyl chloride, PVC) was prepared using emulsion polymerisation, as previously 
reported by the authors27.  When required, coating of the hydrogels onto PVC was 
performed using a modification to the method described by McGinty and Brittain28.  In 
this a section of PVC film (3cm x 3cm x 200µm) was immersed in a solution of monomer 
(HEMA, or various ratios of HEMA:MAA) containing 2,2’-azobisisobutyronitrile and 
ethylene glycol dimethacrylate, as described above.  The mixture was covered and 
heated to 60°C in a thermostatically controlled oven until the acrylate layer became 
viscous. The sample was then removed and pressed between two glass plates before 
being returned to the oven at 60°C for 18 hours.  Samples were removed and soaked in 
deionised water for 24 hours to remove remaining unpolymerized monomer. 
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2.4 Analysis of gentamicin using high performance liquid chromatography 
Due to the lack of a suitable chromophore, pre-column derivatisation of gentamicin was 
performed by reaction with excess 2,4-dinitrofluorobenzene.  In this gentamicin was 
reacted with excess fluoro-2,4-dinitrobenzene-40 µl (50 mg in 1 mL acetonitrile), 100 µL 
Tris buffer (165 mM, pH 12.0), 200 µl acetonitrile, and 24 µL of analyte solution, heated 
at 85°C in a shaking water bath for 1 hour in a sealed Eppendorf tube.  Following this 
cooling was performed in an ice bath and the solutions were transferred to HPLC 
stoppered vials. HPLC analyses were performed on Shimadzu (Kyoto, Japan) HPLC 
instrumentation consisting of a model SIL-10AD VP auto injector, a model SCL-10A VP 
system controller, a model SPD-10A VP UV-VIS detector and LC-10AT VP liquid 
chromatograph (Dyson Instruments Ltd, Tyne & Wear, UK). The Symmetry® C18 
reverse phase column (100 mm x 4.6 mm, 3.5 µm) was obtained from Waters (MA, 
USA). HPLC analysis of the analyte solution (150 μL) containing derivatised gentamicin 
was performed at ambient temperature in isocratic mode, with the mobile phase, 
acetonitrile: Tris Buffer 8.25 mM, pH 7.0 (75:25 v/v), delivered at 1.0mL min-1. 
Components were detected at 365 nm and external standardisation was used. The 
mobile phase was filtered and degassed on a 0.45 μm membrane (Millipore, Bedford, 
MA, USA) before use. The chromatographs obtained were analysed using Shimadzu 
Class VP® software.  The relationship between peak area and concentration was linear 
(r> 0.99) over a concentration range of 5-250 μg mL-1. 
 
2.5 Preparation of gentamicin loaded hydrogels 
Copolymers with a range of HEMA: MAA mass ratios (100:0, 90:10, 80:20, 70:30) were 
loaded with drug by immersion in a buffered gentamicin solution (isotonic Tris, pH 7.4, 
50 mg mL-1 gentamicin sulfate) and placement in a shaking water bath (100 oscillations 
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min-1) at 37°C. Prior to immersion each section of p(HEMA) and p(HEMA-co-MAA) was 
dried in an oven.  After immersion and prior to subsequent analysis of the materials, 
surface gentamicin solution was removed by placing the sample in a meshed metal 
basket and rinsing three times in isotonic Tris buffer, each for five seconds. The sample 
was then gently blotted dry between two pieces of filter paper.  To quantify the mass of 
incorporated gentamicin, the drug was extracted five times into pre-heated buffered 
solution (isotonic Tris pH 7.4) under shaking water conditions (100 oscillations min-1) at 
37°C. The mass of gentamicin in the various extracts was quantified using HPLC, as 
described above. To ensure all gentamicin was extracted, at the end of the analysis the 
samples were ground up in mortar and pestle, placed in fresh Tris buffer and the mass 
of drug quantified.  All analyses were repeated at least five times. 
 
2.6 Buffer uptake of p(HEMA) and p(HEMA-co-MAA) hydrogels 
Samples of hydrated p(HEMA) and p(HEMA-co-MAA) were prepared and dried in an 
oven until a steady state weight was achieved. The discs were then accurately weighed, 
transferred to stoppered vials containing Tris buffer (pH 7.4, isotonic) and incubated 
under shaking conditions at 37ºC. At pre-selected times each sample was removed, 
blotted dry between 2 pieces of filter paper and then reweighed before being returned 
to the stoppered vial containing Tris buffer (pH 7.4) until the next time period.  The 
buffer uptake was defined as the swelling ratio (SR) using the following equation.  At 
least five replicate analyses were performed. 
 
 
Where: 
!!
  
SR =
Ww −Wd
Wd
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Ww is the wet weight of the sample 
Wd is the dry weight of the sample 
 
2.7 Determination of hydrogel network parameters 
From the swelling data the following network parameters were calculated29: 
(i) The molecular weight of the polymer chain between two neighbouring cross-
links (𝑀!) (g mol-1) M! = −d!V!ϕ !! !  [ln 1 − ϕ  + ϕ +  χϕ! ]!! 
Where: 
dp is the density of the polymer (g cm-1) 
Vs is the molar volume of the solvent (18 cm3 mol-1) 
Χ is the Flory-Huggins interaction parameter  
(Calculated as χ = 0.5 +  !!) 30 
ϕ is the volume fraction of the polymer in the swollen state, calculated using: 𝜙 =  [ !!!! !!! !!!! + 1]!!, Where, in addition to the above: 
 ds is the density of the solvent (g cm-3) 
 W∞ is the weight of the hydrogel at equilibrium 
 Wo is the dry polymer weight 
 
(ii) Cross-link density (mol cm-3, ρ) 
ρ =  d!M! 
(iii) Mean pore size (nm) of the polymeric network of the hydrogel (ζ) 
𝜁 =   0.071𝜙(!! !) M! 
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2.8 Tensile analysis  
The mechanical properties of the various equilibrium-hydrated hydrogels were 
determined using a Stable Micro Systems TA-XT2 Texture Analyser, as previously 
reported by the authors25. Tensile analysis was performed in accordance with the 
American Standards for Testing Materials guidance number D 638M. Dumbbell-shaped 
samples were fashioned from equilibrium-hydrated hydrogels and excess moisture was 
removed by gently patting the surface with filter paper.  The samples were then 
immediately fixed between the clamps (mobile upper and static lower clamp) and held 5 
cm apart with the aid of two adhesive pads (Sellotape® Sticky Fixers™).  The upper 
clamp was raised at a constant crosshead speed of 1.0 mm s-1 until sample fracture 
occurred.   In all cases at least 5 replicates of each analysis were performed. From the 
resultant relationship between the stress and strain, the ultimate tensile strength, 
Young’s Modulus and % elongation at break were calculated. 
 
2.9 Modulated temperature differential scanning calorimetry (MTDSC)  
The glass transition temperatures of dried p(HEMA) and p(HEMA-co-MAA) hydrogels 
were analysed using a DSC 2920 Modulated DSC (TA Instruments, Leatherhead, UK) in 
modulated temperature mode with an attached refrigerated cooling system (RCS) unit. 
Calibration of the instrument was conducted using the melting of indium, cyclohexane 
and tin standards. Nitrogen was used as the purge gas, flowing at a rate of 30mL min-1 
through the DSC cell and at 150 mL min-1 through the RCS unit. The mass of each 
empty sample pan matched the mass of the empty reference pan to ± 0.1mg. TA 
Instruments aluminium pinhole hermetic pans were used throughout the experiments.  
Each analysis consisted of an initial two minute isothermal period at 25 °C followed by a 
modulation amplitude of ± 0.21°C every 40 seconds with a 2°C min-1 underlying heating 
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rate to 200°C.  Experiments were repeated at least 5 times for each candidate hydrogel.  
Modelling of the data was performed using the Gordon-Taylor equation31. 
 
2.10 Gentamicin release 
The release of gentamicin from the hydrogels as a function of time (under sink 
conditions) was performed by immersion of polymer samples in McCartney 
bottles that contained pre-heated buffer (30mL, isotonic Tris, pH 7.4) which were 
then placed in a water bath under shaking conditions (100 oscillations min-1) at 
37°C. Prior to placement in the pre-heated isotonic buffer solution, excess surface 
solution was removed from the sample.  At selected time intervals hydrogel 
samples were removed and immersed in fresh, pre-heated buffer (isotonic Tris, 
pH 7.4) to ensure sink conditions32, 33. The mass of gentamicin released was then 
quantified by HPLC as described above. 
 
2.11 Bacterial adherence to p(HEMA) and p(HEMA-co-MAA) hydrogels both 
containing and devoid of with gentamicin 
Adherence of stationary phase bacteria to p(HEMA) and p(HEMA-co-MAA) hydrogels 
(either devoid of or containing gentamicin as defined in section 2.5) was examined 
using a modification of a method previously reported by the authors27, 34.  In this, a 
volume (20 mL, circa 1 x108 colony forming units mL-1) of the bacterial suspension was 
added to McCartney bottles, each of which contained three hydrogel discs placed on a 
needle. The bottles were incubated in an orbital incubator (37°C, 100 oscillations min-1) 
for periods of 1, 4 and 24 hours. Upon removal at the pre-selected times, the needles 
with attached samples were washed gently three times with 20 mL sterile peptone 
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water to remove any non-adherent bacteria. Adherent bacteria were removed by 
placing the individual hydrogel discs in 10 mL volumes of peptone water, sonicating in 
an ultrasonic bath for 5 minutes and vortexing for 30 seconds. The number of adherent 
bacteria to each biomaterial was then determined by serial dilution. 
 
2.12 Bacterial viability on p(HEMA) and p(HEMA-co-MAA) hydrogels following 
exposure to nebulised gentamicin 
In this method, samples of PVC with an attached hydrogel coating were prepared 
(surface area 25 cm2), fixed in position using a clamp and exposed to gentamicin 
via nebulisation (4 mL, 80 mg for 20 minutes) or to isotonic Tris buffer (pH 7.4, as a 
control). The distance between the nebuliser and the material was maintained at 5 cm.  
The dose and duration of nebulisation was selected on the basis of a previous report10.  
A suspension of bacteria (4 mL circa 1 x 109 colony forming units mL-1) was then 
aseptically transferred into the Hudson Micro Mist® small volume nebulising chamber 
which was attached to the small volume nebuliser (DeVilbiss SunMist Plus®).  The 
nebuliser was aimed at the hydrogel coatings and was permitted to run for a period of 
thirty minutes after which time samples of each material were removed from the 
material and viable bacterial adherence calculated as described above.  
 
2.13 Examination of antimicrobial persistence  
A volume (0.5 mL) of stationary phase S. aureus or Ps. aeruginosa (circa 2 x107 colony 
forming units mL-1) was added to a sterile Petri dish and molten agar (20mL Mueller 
Hinton Agar) added. The dish was swirled to adequately mix the agar and then allowed 
to solidify. A gentamicin containing hydrogel sample (prepared as described in the 
materials and methods) was placed onto the agar surface using sterile forceps and the 
 15 
dish incubated at 37°C for 18 hours. After this period the zones of complete inhibition 
were measured (n ≥ 5 in each case).  To investigate the persistence of activity of these 
materials the sample discs were removed from the agar plates after the first 18 hours of 
incubation and transferred, using sterile forceps, to a freshly seeded plate (S. aureus 
and Ps. aeruginosa respectively) and incubated for a further 18 hours. The persistence 
of activity was determined by transferring the samples to fresh seeded plates after each 
incubation period until no further zones were produced.  
 
2.14 Statistical analysis 
All experiments were performed at least five times and the results expressed as the 
mean ± standard deviation. The effect of hydrogel composition on the mechanical 
properties, swelling properties, network parameters, drug loading and bacterial 
adherence (at each sampling point) were statistically evaluated using a one-way 
Analysis of Variance (ANOVA).  The effects of hydrogel composition on gentamicin 
release and on the persistence of antimicrobial activity in the zone of inhibition assay 
were statistically evaluated using a repeated measures one-way ANOVA.  Individual 
differences between the various materials in the above analyses were statistically 
identified using Tukey’s HSD test. Linear regression analysis was performed when 
required and the significance of this assessed using the one-way ANOVA in association 
with examination of residuals.  In all cases a probability of p < 0.05 was selected to 
denote significance. 
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3. Results and Discussion 
The use of aerosolised antibiotics has been reported to be a successful strategy to 
prevent/reduce the incidence of ventilator-associated pneumonia.  For example, Adair 
et al.10 compared the efficacy of nebulised gentamicin with that of conventional 
antibiotic prophylaxis to prevent the formation of microbial biofilm on the ET tubes of 
ICU patients.  In this no pathogens were recovered from the ET tubes which received 
nebulised gentamicin, whereas Wood et al. reported a reduction of 73% in the 
incidence of VAP in those patients assigned nebulised ceftazidime compared to 
patients who received placebo after two weeks35.  One limitation of these approaches, 
which this current study addresses, is the poor retention of the nebulised antimicrobial 
agent at the inner surface of the endotracheal tube.  The location of the nebulised 
antimicrobial agent within a coating on the luminal surface of the tube will serve to 
concentrate and localise the antimicrobial agent, thereby offering an enhanced 
antimicrobial effect against adherent microorganisms, a lower required frequency of 
nebulisation and minimisation of the possible emergence of resistant bacterial strains.   
 
3.1 Attachment of Hydrogels to PVC 
To perform as an effective coating, it is essential to ensure that the coating remains 
attached to the polymeric substrate. In this study successful, irreversible coating of 
PVC was performed using a modification of the method of McGinty and Brittain28 and 
resulted in hydrogel layers of approximately 200 µm thickness on a PVC substrate.  
Attachment of the coating to the substrate was robust and homogeneous following 
equilibrium swelling.  
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3.2 Physicochemical Properties of Hydrogels 
The hydrogel systems described in this study are designed as coatings for PVC ET 
tubes and therefore the bulk mechanical properties of the coated ET tubes would be 
principally derived from the PVC component.  However, it is important that the 
mechanical properties of the coatings are sufficiently robust to withstand the normal 
deformations encountered during insertion and removal of the device.  Mechanical 
failure of the coating may result in shedding into the lungs, which will have implications 
for respiratory function.   
 
The effect of material composition on the mechanical properties of the hydrogels and 
the glass transition temperatures of the xerogels are shown in table 1. As may be 
observed, the glass transition temperatures of the dehydrated materials were 
dependent on the MAA content.  The glass transition temperature of p(HEMA) was 
114.94 ± 1.58°C and this was sequentially (and linearly) raised by increasing the 
composition of MAA, with the glass transition temperature of p(HEMA-co-MAA, 70:30) 
being 146.76 ± 3.57°C.  Modelling of the glass transition data was performed using the 
Gordon-Taylor equation31, from which it was confirmed that a positive correlation 
between glass transition temperature and weight fraction of p(HEMA) existed.  Based 
on this information it may be concluded that the hydrogels were copolymers and not 
polymer blends36. 
 
The mechanical properties of the equilibrium-swollen hydrogels under examination 
were dependent on the mass of MAA but not on the presence of gentamicin.  
Increasing the MAA composition of the materials significantly decreased the % 
elongation at break, the ultimate tensile strength and the Young’s modulus.  The 
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inability of gentamicin to adversely affect the mechanical properties illustrates that, 
whilst this drug may interact with the carboxylic acid group of the MAA-containing 
hydrogels37, 38, this interaction is insufficient to compromise the mechanical properties 
of the swollen hydrogels.  The mechanical properties of the hydrogel coatings were 
directly dependent on the ratio of HEMA:MAA.  Decreasing the HEMA:MAA ratio 
significantly and sequentially decreased the ultimate tensile strength, elongation 
at break and Young’s modulus.  These observations may be accredited to the 
effects on MAA on the molecular weight of the polymer chain between two 
neighbouring cross links.  The effects of MAA on the mechanical properties of 
HEMA are in accordance with previous reports39, 40.  Despite the reductions in the 
mechanical properties associated with the incorporation of MAA within the copolymers, 
the magnitude of these properties would be sufficient as coatings on PVC.  The 
hydrogels were able to withstand considerable deformation and shear stresses, such as 
those experienced upon insertion/removal of the ET tubes, prior to fracture.   
 
3.3 Hydrogel Swelling Studies and Network Parameters 
The buffer uptake properties of p(HEMA) and p(HEMA-co-MAA) are displayed in Figure 
1.  As may be observed the relationship between swelling ratio and time was non-linear 
for each material.  The greatest swelling ratio (at equilibrium uptake) was exhibited by 
the copolymer composed of p(HEMA-co-MAA, 70:30) (3.56 ± 0.34) whereas the lowest 
swelling ratio was associated with p(HEMA) homopolymer (0.57 ± 0.01).  The other 
materials exhibited swelling ratios that were significantly different from one another and 
lay between these values.  Modelling of the swelling properties was performed using a 
power law model to provide information on the mechanism of swelling, defined using 
the exponent (n) (Table 2)37, 41.   From this it was observed that the exponent 
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significantly increased as the mass of MAA was increased within the biomaterials.  
Hence the greatest exponent was displayed by p(HEMA-co-MAA, 70:30) whereas the 
lowest value of this parameter was associated with p(HEMA).  The ability of copolymers 
of HEMA:MAA to exhibit greater swelling than p(HEMA) is accredited to  the ability of 
the hydrogels to ionise and undergo charge-mediated, polymer chain repulsion42.  
Consideration of the swelling exponents confirmed that the mechanism of buffer uptake 
by p(HEMA) and the various copolymers was anomalous and is in accordance with a 
combination of factors, including the rate of ionisation at the glassy/rubbery interface37.  
The uptake of gentamicin was directly related to the swelling properties; with materials 
exhibiting increased swelling showing the greatest mass of absorbed gentamicin (Table 
2).  Accordingly, decreasing the ratio of HEMA to MAA in the hydrogels significantly 
increased the loading of gentamicin, reaching a maximum at a hydrogel ratio of 70:30.  
 
The network parameters associated with the various hydrogels, calculated using 
swelling data29, are presented in Table 2.  As the ratio of HEMA:MAA within the 
hydrogels was decreased sequentially from 100:0 to 70:30 the molecular weight of the 
polymer chain between two neighbouring cross links and the mesh size increased 
whereas the cross link density and the volume fraction of the polymer in the swollen 
state decreased.  Accordingly, as the mass of MAA within the hydrogels increased (and 
at physiological pH under which conditions there is >99% ionisation of the carboxylic 
acid groups), the increased mesh size facilitated fluid absorption.  The uptake of 
gentamicin into the fluid filled regions between the polymer chains was dependent on 
the mesh size.  Assuming the hydrodynamic radius of gentamicin is similar to that of 
other small organic drug molecules43, the lower mesh size of p(HEMA) (1.81±0.00nm) 
will act to preclude drug uptake within the mesh volume.  As the mesh size increases 
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the uptake of gentamicin increases thereby facilitating gentamicin uptake.  The uptake 
of gentamicin into the hydrogel composed of 70:30 HEMA:MAA (mesh size 
39.18±1.83nm) was greater than into the hydrogel composed of 80:20 HEMA:MAA 
hydrogel (mesh size 33.64±1.59nm) however the extent of the uptake of gentamicin into 
the 90:10 HEMA:MAA hydrogel  (mesh size 24.43±1.02nm) was markedly less.  
Accordingly a mesh size of >30nm facilitates substantial loading of this hydrogel with 
gentamicin. 
 
3.4 Gentamicin Release from Hydrogels 
The composition of the hydrogels significantly affected the subsequent mass of 
gentamicin released as a function of time (Figure 2a).  The release of gentamicin from 
p(HEMA) was rapid and uncontrolled (with low released mass) due to the low drug 
loading (and surface location) of gentamicin (data not shown).  Consequently 100% 
drug release had occurred by the first sampling period (15mins). The overall mass of 
drug released was dependent on the initial drug loading (table 2), which was, in turn, 
significantly affected by the composition of the hydrogel.  Figure 2b represents the data 
as the fractional drug release to facilitate comparison of the release rates of the 
gentamicin from the three hydrogels.  As may be observed, the release of gentamicin 
was relatively rapid from the hydrogel co-polymers, with 50% release occurring within 
the first 15 minutes.  The release rates of gentamicin from the hydrogels composed of 
90:10 and 80:20 HEMA:MAA were statistically similar.  These observations are in line 
with other publications in which a rapid release of therapeutic agents from 
p(HEMA)-based hydrogels has been reported, e.g. Alfuzosin Hydrochloride44, 
Timolol Maleate45 and Ciprofloxacin Hydrochloride46. 
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Based on these observations, the p(HEMA) hydrogel did not offer suitable properties 
(drug uptake and release) to be considered as a suitable as a gentamicin capture 
coating designed for the prevention of ventilator-associated pneumonia.  However, the 
properties of the other co-polymers showed promise in this regard. 
 
3.5 Antimicrobial and Microbial Anti-Adherence Properties of Hydrogels  
The National Nosocomial Infection Surveillance (NNIS) system reported that mechanical 
ventilation was implicated in 83% of episodes of nosocomial pneumonia, with 
endotracheal intubation cited as an obvious predisposing factor for ventilator-
associated pneumonia47.  S. aureus and Ps. aeruginosa have emerged as the principal 
causative organisms of ventilator-associated pneumonia48, 49. Therefore clinical isolates 
of these pathogens were selected to evaluate the antimicrobial properties of the 
candidate hydrogels.  These properties of the hydrogels were assessed in terms of their 
resistance to microbial adherence and the persistence of antimicrobial activity, the 
latter assessed using a seed plate method.  Microbial adherence to biomaterials is 
accepted to represent the initial stage of medical device colonisation38, 50, 51 and thereby 
reduction/inhibition of this process represents a critical stage in the development of 
infection resistance medical biomaterials.  The effects of gentamicin treatment and time 
on the adherence of S. aureus and Ps. aeruginosa to p(HEMA) and p(HEMA-co-MAA) 
hydrogels are displayed in Tables 3 and 4, respectively.  The composition of the 
hydrogels and the contact time significantly affected microbial adherence.  However, 
whilst individual differences in the time and hydrogel composition were observed, no 
overall trends were observed.  More importantly, gentamicin-containing hydrogel 
copolymers inhibited the adherence of both microorganisms at each time period 
studied.   Conversely, adherence of both microorganisms to gentamicin-loaded 
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p(HEMA) was observed however, this was significantly lower (> 90% reduction) than to 
p(HEMA) devoid of gentamicin.  The inability of gentamicin-containing p(HEMA) 
hydrogel to inhibit adherence is directly related to the low drug loading and negligible 
drug release from this biomaterial.   
 
 
The persistence of antimicrobial activity, expressed as zones of inhibition of the various 
gentamicin-containing hydrogels against Ps. aeruginosa and S. aureus, are shown in 
Figures 3 and 4, respectively.  It should be noted that the results illustrate the 
persistence of the hydrogels obtained by following the antimicrobial activity over 
sequential transfers.  This method is useful for two reasons.  Firstly, the antimicrobial 
activity of the hydrogels may be examined following a series of successive microbial 
challenges.  Secondly, as the antimicrobial activity in this method results from diffusion 
of drug from the hydrogel, this method provides an indication of drug release under 
non-sink conditions.  Given that when used in vivo the fluid content on the luminal 
side of the ET tube (to which the hydrogel is attached) will be minimal (and only 
results from the nebulisation process and the inspiration of humid air), the 
conditions under which drug release will occur will be non-sink.  Therefore, this 
method is of particular relevance given the non-sink conditions that operate in 
vivo.  As may be observed, all hydrogel polymers exhibited antimicrobial persistence, 
denoted by the significant zones of inhibition on successive days, against S. aureus and 
Ps. aeruginosa.  Maximum antimicrobial persistence against both bacteria was 
associated with the hydrogel copolymer composed of 70:30 HEMA: MAA, with 
persistence lasting >30 days and >20 days for S. aureus and Ps. aeruginosa, 
respectively.  Significant differences in antimicrobial persistence between each 
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hydrogel were observed however, for both microorganisms, p(HEMA) had minimal 
antimicrobial persistence, due to the low drug loading and rapid release of gentamicin 
from this biomaterial. 
 
To simulate the performance of these hydrogel systems under clinical conditions, 
this study examined the ability of the coatings that had been pre-treated by 
nebulisation with a solution of gentamicin (using a clinical nebuliser) or Tris buffer 
(as a control) and then exposed to nebulised bacteria, to resist microbial 
colonisation on the surface of the coating.  Microbial survival on exemplar hydrogels 
either containing or devoid of (nebulised) gentamicin is shown in Table 5. Following 
nebulisation of both microorganisms on each control (non-gentamicin treated) material 
microbial colonisation resulted, the extent of which was dependent on the composition 
of the hydrogel. Importantly, microbial colonisation on the p(HEMA: MAA) copolymers 
that had previously been exposed to gentamicin via nebulisation was not observed.  
Conversely, microbial adherence was observed on p(HEMA) that had previously been 
exposed to gentamicin however, the extent of this was dramatically lower than to 
control (non-treated) p(HEMA).  In this experimental method, gentamicin was not 
released into a bathing solution and therefore the concentration and availability of 
gentamicin relates to the concentration of this antimicrobial agent within the aqueous 
filled pores of the polymer matrix.  Upon contact with the hydrogel, the bacteria will be 
in direct contact with this gentamicin-containing aqueous interface and therefore 
gentamicin will be directly available to exert its antimicrobial effect.  Furthermore, it 
should be noted that the available gentamicin concentration will far exceed that which 
may be obtained following administration of this drug by other means10.  The activity of 
p(HEMA) was inferior to the hydrogel copolymers and may be accredited to the lower 
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uptake of gentamicin within the matrix of this polymer following nebulisation and hence 
the lower availability of antimicrobial agent.   
 
4. Conclusions 
This study uniquely describes a novel pharmaceutical strategy for the prevention of 
ventilator-associated pneumonia, in which candidate hydrogel coatings (p(HEMA) and 
p(HEMA-co-MAA)) on PVC have been designed to entrap gentamicin following 
nebulisation of solutions of this antimicrobial agent.  The physicochemical properties of 
the hydrogels, namely the uptake of gentamicin, swelling, gentamicin release, 
mechanical properties and calculated network parameters were dependent on the ratio 
of HEMA to MAA.  Microbial (S. aureus and Ps. aeruginosa) adherence to control (non-
gentamicin containing) coatings was dependent on the coating composition.  Following 
the inclusion of gentamicin, either by immersion in or by nebulisation of a solution of 
gentamicin, microbial growth on the hydrogel copolymers was not observed, however, 
growth was observed on p(HEMA).  Similarly, antimicrobial persistence (determined 
using zone of inhibition measurements against both microorganisms on successive 
days) was observed for the hydrogel copolymers (> 20 days) whereas only limited 
persistence was associated with gentamicin-containing p(HEMA).  These observed 
differences were directly related to the rate and extent of gentamicin uptake.   In light of 
the excellent antimicrobial activity and physicochemical properties, p(HEMA: MAA) 
copolymers composed of ratios of 80: 20 or 70: 30 HEMA: MAA are useful coatings of 
endotracheal tubes to be used in conjunction with the clinical nebulisation of 
gentamicin.  It is proposed that the use of these coatings in conjunction with gentamicin 
nebulisation would be beneficial for the prevention of ventilator-associated pneumonia. 
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Legends 
Figure 1.   The effect of hydrogel composition on the swelling ratio (Tris buffer, 
pH 7.4 containing 50 mg mL-1 gentamicin sulfate).  Symbols: closed circles p(HEMA), 
closed diamonds 90:10 p(HEMA-co-MAA), closed triangles 80:20 p(HEMA-co-MAA), 
closed squares 70:30 p(HEMA-co-MAA), open triangles 60:40 p(HEMA-co-MAA). 
 
Figure 2. The effect of hydrogel composition on gentamicin release (Tris buffer, pH 
7.4). Figure 2a expresses drug release in terms of the cumulative mass of gentamicin 
released as a function of time whereas Figure 2b expresses the fractional drug released 
as a function of time.  Symbols: closed diamonds 90:10 p(HEMA-co-MAA), closed 
triangles 80:20 p(HEMA-co-MAA), closed squares 70:30 p(HEMA-co-MAA 
 
Figure 3. The effect of hydrogel composition on the zone of inhibition of Ps. 
aeruginosa. Symbols: closed circles p(HEMA), closed diamonds 90:10 p(HEMA-co-
MAA), closed triangles 80:20 p(HEMA-co-MAA), closed squares 70:30 p(HEMA-co-
MAA) 
 
Figure 4. The effect of hydrogel composition on the zone of inhibition of S. aureus. 
Symbols: closed circles p(HEMA), closed diamonds 90:10 p(HEMA-co-MAA), closed 
triangles 80:20 p(HEMA-co-MAA), closed squares 70:30 p(HEMA-co-MAA) 
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